Prostate Seed Implants

Reports on the Effectiveness of Taxotere for Treating Prostate Cancer

  1. DiPaola, R.S., Approaches to the treatment of patients with hormone-sensitive prostate cancer. Semin Oncol, 1999. 26(5 Suppl 17): p. 24-27.

  2. Kang, M.H., W.D. Figg, and W. Dahut, Taxanes in hormone-refractory prostate cancer. Cancer Pract, 1999. 7(5): p. 270-72.

  3. Milas, L., M.M. Milas, and K.A. Mason, Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol, 1999. 9(2 Suppl 1): p. 12-26.

  4. Friedland, D., et al., A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol, 1999. 26(5 Suppl 17): p. 19-23.

  5. Picus, J. and M. Schultz, Docetaxel (Taxotere) as monotherapy in the treatment of hormone- refractory prostate cancer: preliminary results. Semin Oncol, 1999. 26(5 Suppl 17): p. 14-18.

  6. Petrylak, D.P., et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 1999. 17(3): p. 958-67.

  7. Petrylak, D.P., et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 1999. 17(3): p. 958-67.

  8. Kwok, Y., DiBiase, S.J., Amin, P.P., Naslund, M., Sklar, G., Jacobs, S.C.; Risk Group Stratification in Patients Undergoing Permanent Iodine 125 Prostate Brachytherapy As Monotherapy. Int.J.Radiation Oncology Biol.Phys., Vol. 53, No. 3, pp.588-594, 2002.

  9. DiBiase, S.J., Dawson, N., Naslund, M., Hussain, A., Kataria, R., Bangalore, M., Dhople, A., Guo, C., and Amin, P.P.; Phase II Study of Combined External Beam Radiation Therapy (EBRT), Brachytherapy (PB), Total Androgen Suppression (TAS), and Adjuvant Docetaxel (AD) in Poor-Risk, Localized Prostate Cancer (PCa). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 22, No. 14S (July 15 Supplement), 2004:4764.

This page was last updated on: March 5, 2008.